COuldn't agree more. I actually held RGS for years, but got out...

COuldn't agree more. I actually held RGS for years, but got out higher up, only to get back in recently at lower levels. Didn't think I'd get another chance after Japanese advancements, but how quickly the market forgets. Dare I say it but after some terrible primary endpoint selections and poor discourse with FDA etc, MSB might finally be about to get some luck. I think the whole sector is vastly undervlaued, but RGS management need to be a little more animated to the capital mkts on which they still rely to be an ongoing concern.